Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Moodys
Queensland Health
McKinsey
Medtronic
Federal Trade Commission
Cerilliant
Fish and Richardson
Fuji

Generated: July 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,072,781

« Back to Dashboard

Summary for Patent: 9,072,781
Title:Morphine formulations
Abstract: Provided herein, generally, are pharmaceutical formulations, e.g., injectable pharmaceutical formulations with improved stability, comprising morphine sulfate or a hydrate thereof, and methods of producing and using the same. Also provided herein are kits comprising the formulations, e.g., injectable morphine formulations.
Inventor(s): Cuine; Alain (St. Fargeau-Ponthierry, FR), Hoarau; Didier (Claix, FR), Romain; Pauline (Saint Egreve, FR)
Assignee: Becton, Dickinson France S.A.S. (La Pont de Claix, FR)
Application Number:14/207,245
Patent Claim Types:
see list of patent claims
Formulation; Compound; Device;

Drugs Protected by US Patent 9,072,781

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Fresenius Kabi Usa MORPHINE SULFATE morphine sulfate SOLUTION;INTRAMUSCULAR, INTRAVENOUS 204223-001 Oct 30, 2013 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Fresenius Kabi Usa MORPHINE SULFATE morphine sulfate SOLUTION;INTRAMUSCULAR, INTRAVENOUS 204223-002 Oct 30, 2013 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Fresenius Kabi Usa MORPHINE SULFATE morphine sulfate SOLUTION;INTRAMUSCULAR, INTRAVENOUS 204223-003 Oct 30, 2013 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Fresenius Kabi Usa MORPHINE SULFATE morphine sulfate SOLUTION;INTRAMUSCULAR, INTRAVENOUS 204223-004 Oct 30, 2013 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 9,072,781

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,192,608 Morphine formulations ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 9,072,781

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Japan 2016512210 ➤ Sign Up
European Patent Office 3143988 ➤ Sign Up
European Patent Office 2968132 ➤ Sign Up
China 104042565 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Dow
Boehringer Ingelheim
Cerilliant
Johnson and Johnson
Accenture
Argus Health
Baxter
Mallinckrodt
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.